Angelini Pharma and Quiver Bioscience team up to tackle genetic epilepsies

Under the deal, Quiver will receive an undisclosed advance payment and research support

Novo Nordisk’s "Triple G" drug UBT251 triggers nearly 20% weight loss in 24 weeks

UBT251 appeared to have a safe and well-tolerated profile consistent with incretin-based therapies

Dewpoint Therapeutics selects groundbreaking MYC development candidate

MYC, a master regulator of oncogenic transcription, drives multiple high-burden cancers but has long eluded direct pharmacologic control

Iambic taps AI to power multi-year drug discovery deal with Takeda

Onchilles Pharma gets FDA green light for first-in-human trials of breakthrough cancer therapy

N17350 is the company’s first-in-class tumor-directed therapeutic, designed to harness the ELANE pathway

Gradalis’ Vigil therapy dramatically extends survival in advanced ovarian cancer

The randomized, double-blind, placebo-controlled Phase 2b VITAL trial enrolled 91 patients with newly diagnosed Stage IIIb–IV epithelial ovarian cancer

AVEO Oncology doses first patient in pioneering AML clinical trial

The trial aims to assess the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of the combination therapy

Zealand Pharma taps Denmark’s supercomputer to supercharge drug discovery

Gefion, powered entirely by renewable energy, boasts more than 1,500 NVIDIA GPUs

Evotec subsidiary bags Gates Foundation grant to expand global access to biologics

The grant will fund ten new J.MD projects over the next three years, targeting multiple global health threats

Prokaryotics and Basilea team up to tackle deadly fungal infections

The partnership aims to develop a first-in-class broad-spectrum antifungal to combat life-threatening invasive infections